Login to Your Account



Clinical Hold Continues

Dynavax's Heplisav Hits Endpoint in HBV Trial

By Trista Morrison


Thursday, August 7, 2008
Dynavax Technologies Corp. and partner Merck & Co. Inc. said their Phase III trial of hepatitis B vaccine Heplisav met its primary endpoint of inducing a noninferior antibody response compared to GlaxoSmithKline plc's marketed hepatitis B vaccine, Engerix-B. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription